| Surgery versus physical therapy for a meniscal tear and osteoarthritis JN Katz, RH Brophy, CE Chaisson, L De Chaves, BJ Cole, DL Dahm, ... New England Journal of Medicine 368 (18), 1675-1684, 2013 | 804 | 2013 |
| Estimating the burden of total knee replacement in the United States AM Weinstein, BN Rome, WM Reichmann, JE Collins, SA Burbine, ... JBJS 95 (5), 385-392, 2013 | 582 | 2013 |
| The dramatic increase in total knee replacement utilization rates in the United States cannot be fully explained by growth in population size and the obesity epidemic E Losina, TS Thornhill, BN Rome, J Wright, JN Katz JBJS 94 (3), 201-207, 2012 | 568 | 2012 |
| Lifetime risk and age at diagnosis of symptomatic knee osteoarthritis in the US E Losina, AM Weinstein, WM Reichmann, SA Burbine, DH Solomon, ... Arthritis care & research 65 (5), 703-711, 2013 | 465 | 2013 |
| Drug evaluation during the Covid-19 pandemic BN Rome, J Avorn New England Journal of Medicine 382 (24), 2282-2284, 2020 | 211 | 2020 |
| FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012 BN Rome, DB Kramer, AS Kesselheim Jama 311 (4), 385-391, 2014 | 76 | 2014 |
| Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective observational study B Gyawali, BN Rome, AS Kesselheim bmj 374, 2021 | 64 | 2021 |
| Trends in prescription drug launch prices, 2008-2021 BN Rome, AC Egilman, AS Kesselheim JAMA 327 (21), 2145-2147, 2022 | 57 | 2022 |
| Placing a price on medical device innovation: the example of total knee arthroplasty LG Suter, AD Paltiel, BN Rome, DH Solomon, TS Thornhill, SK Abrams, ... PloS one 8 (5), e62709, 2013 | 41 | 2013 |
| US public investment in development of mRNA covid-19 vaccines: retrospective cohort study HS Lalani, S Nagar, A Sarpatwari, RE Barenie, J Avorn, BN Rome, ... bmj 380, 2023 | 35 | 2023 |
| Market exclusivity length for drugs with new generic or biosimilar competition, 2012–2018 BN Rome, CWC Lee, AS Kesselheim Clinical Pharmacology & Therapeutics 109 (2), 367-371, 2021 | 33 | 2021 |
| Approval of high-risk medical devices in the US: implications for clinical cardiology BN Rome, DB Kramer, AS Kesselheim Current cardiology reports 16, 1-9, 2014 | 32 | 2014 |
| New reforms to prescription drug pricing in the US: opportunities and challenges TJ Hwang, AS Kesselheim, BN Rome Jama 328 (11), 1041-1042, 2022 | 30 | 2022 |
| Simulated Medicare drug price negotiation under the Inflation Reduction Act of 2022 BN Rome, S Nagar, AC Egilman, J Wang, WB Feldman, AS Kesselheim JAMA Health Forum 4 (1), e225218-e225218, 2023 | 29 | 2023 |
| Non-warfarin oral anticoagulant copayments and adherence in atrial fibrillation: a population-based cohort study BN Rome, JJ Gagne, J Avorn, AS Kesselheim American Heart Journal 233, 109-121, 2021 | 28 | 2021 |
| A comparison of patient-reported and measured range of motion in a cohort of total knee arthroplasty patients JE Collins, BN Rome, ME Daigle, V Lerner, JN Katz, E Losina The Journal of arthroplasty 29 (7), 1378-1382. e1, 2014 | 28 | 2014 |
| Multiple low doses of intravenous corticosteroids to improve early rehabilitation in total knee arthroplasty: a randomized clinical trial D Li, J Zhao, Z Yang, P Kang, B Shen, F Pei The Journal of Knee Surgery 32 (02), 171-179, 2019 | 27 | 2019 |
| Estimating rebates and other discounts received by Medicare Part D WB Feldman, BN Rome, VC Raimond, JJ Gagne, AS Kesselheim JAMA Health Forum 2 (6), e210626-e210626, 2021 | 25 | 2021 |
| Correlation between changes in brand-name drug prices and patient out-of-pocket costs BN Rome, WB Feldman, RJ Desai, AS Kesselheim JAMA Network Open 4 (5), e218816-e218816, 2021 | 25 | 2021 |
| Transferrable market exclusivity extensions to promote antibiotic development: an economic analysis BN Rome, AS Kesselheim Clinical Infectious Diseases 71 (7), 1671-1675, 2020 | 21 | 2020 |
Aaron KesselheimProfessor of Medicine, Harvard Medical School & Brigham and Women's HospitalAdresse e-mail validée de partners.org
